Use of digital technology tools to examine patient adherence to a prescription omega-3 polyunsaturated acids therapy intended to mitigate cardiovascular risk: protocol and preliminary demographic data from the DIAPAsOn prospective observational study

Gregory P. Arutyunov MD, PhD,¹ Alexander G. Arutyunov MD, PhD,²
Fail T. Ageev MD PhD,³ Tatiana V. Fofanova MD, PhD⁴

¹Department of Internal Medicine, Pirogov Russian National Research Medical University, Moscow. e-mail: arut@ossn.ru

ORCID: 0000-0002-6645-2515

²Department of Internal Medicine, Pirogov Russian National Research Medical University, Moscow. email: agaryunov@mail.ru

ORCID: 0000-0003-1180-3549

³Department of Outpatient Medical and Diagnostic Technologies, Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology, Moscow. email: ftageev@gmail.com

ORCID: 0000-0003-4369-1393

⁴Department of Outpatient Medical and Diagnostic Technologies, Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology, Moscow. email: t.fofanova@yandex.ru

ORCID: 0000-0002-3321-2902

Keywords: Omega-3-acid ethyl esters; myocardial infarction; hypertriglyceridemia, adherence; compliance; persistence; mhealth; ehealth; patient-reported outcomes

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Sustained adherence and persistence with prescription medications is considered essential to achieve maximal treatment benefit for patients with major chronic non-communicable diseases such as hyperlipidemia and lipid-associated cardiovascular disease. It is widely documented, however, that a large percentage of patients with these conditions have poor longer-term compliance with their treatments. The population of Russia is affected by poor compliance in the same ways as populations elsewhere and continues to have high rates of cardiovascular disease.

Hypertriglyceridemia is suspected of contributing to residual cardiovascular risk in patients whose low-density lipoprotein cholesterol (LDL-C) is well controlled. A preparation of highly purified omega-3 polyunsaturated fatty acids (EPA/DHA=1.2/1-90%, marketed as OMACOR), is indicated for the control of high triglyceride levels and also for secondary prevention of myocardial infarction (MI).

DIAPAsON is a prospective observational program designed to evaluate the impact of digital technologies on patient compliance and adherence in a large sample of patients whose treatment scheme includes EPA/DHA=1.2/1-90%. A bespoke electronic data capture system has been developed for this purpose that enables information obtained during clinic visits to be supplemented by remote patient self-reporting. Other objectives of the program include raising patients' awareness about their condition via educational materials available in patient personal accounts in the electronic system.

This report outlines the rationale and methodology of DIAPAsOn and the primary demographics of the study population.

Introduction

Low-density lipoprotein cholesterol (LDL-C), the primary lipoprotein component of total cholesterol (TC), is recognized as the most important lipid risk factor for coronary heart disease (CHD). An extensive array of clinical trials has demonstrated the value of lowering LDL-C as a means of prevention (especially secondary prevention) of major cardiovascular events, including myocardial infarction (MI) and stroke. These findings underpin the status of statins as first-line therapies to reduce cardiovascular risk via modulation of LDL-C levels. The Cholesterol Treatment Trialists (CTT) meta-analysis, which incorporated data from >90,000 patients in 14 randomized controlled trials, exemplifies the influence of LDL-C levels on cardiovascular risk: every 1 mmol/l (39 mg/dl) reduction in LDL-C leads to a decrease in overall mortality of 12%, a 19% reduction in coronary mortality and a 17% reduction in the incidence of stroke, with the effect size relating closely to the absolute reduction in LDL-C achieved and evident across the continuum of LDL-C levels [1,2].

Nevertheless, 5-year event rates in statin-treated patients in the CTT meta-analysis were 14% (compared with 18% in the reference group), and even higher residual risk was apparent in patients with pre-existing CHD or type 2 diabetes [1]. It has been estimated that some 50% of individuals who present with acute coronary syndrome (ACS) do not have elevated LDL-C, indicating that other factors account for a sizeable proportion of total cardiovascular risk [3].

The existence of residual risk in patients whose LDL-C is well controlled with medication [4,5] has focused attention on additional contributors to that persisting risk, including elevated plasma triglyceride (TG) levels [6]. Demonstration of a causal link between elevated TG and cardiovascular risk has been a matter of controversy, with evidence of an association between TG levels and cardiovascular risk often being attenuated after adjustment for other factors [7-11]. Considerations such as the reciprocal relation between levels of TG and levels of high-density lipoprotein cholesterol (HDL-C) (a correlation that persists even when TG are low) [12], as well as appreciation of qualitative metabolic interplay between TG-rich lipoproteins and HDL-C fractions, have nevertheless established a strong prima facie case for TG

levels as one factor influencing residual cardiovascular risk in statin-treated patients, especially in patients characterized by a high TG:HDL-C ratio. Various national and international guidelines recognize that elevated TG may be implicated in the overall risk of CHD [13-15], notably so in patients with type 2 diabetes mellitus, obesity or metabolic syndrome [16-19].

Highly purified long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs), available as prescription-only medications, are approved in various countries for the management of elevated TG. These preparations are qualitatively distinct from dietary supplements of n-3 PUFAs [20]. One such prescription n-3 PUFA preparation (EPA/DHA=1.2/1-90%OMACOR, Market Authorization Holder Abbott Laboratories GmbH, Germany), is available in Russia as 1g capsules containing approximately 840 mg of eicosapentanoic acid and docosahexanoic acid and is approved for use at doses of 2–4 g/day for the regulation of TG. EPA/DHA=1.2/1-90% is also approved, at a daily dose of 1 g, for the secondary prevention of major cardiovascular events in patients who have survived an MI, an indication supported by the findings of a randomized clinical trial and corroborated by a recent Cochrane review [21].

Continuance with therapy is central to the attainment of full and sustained treatment benefit in cardiovascular prevention, as in a range of other major non-communicable diseases. Patients' sense of 'ownership' of their situation, and the accompanying sense of empowerment, can be an important determinant of willingness to persevere with a course of therapy [22]. This can be a challenge when dealing with initially symptomless conditions such as hyperlipidemia, where the connection between symptomless aberrations in blood lipid levels and later major cardiovascular events can seem abstract.

The emergence of widely available digital and internet technologies with the potential to provide rapid or immediate bidirectional communication between healthcare professionals and patients may be an important new resource for promoting long-term adherence to therapies [23]. The DIAPASOn study was designed to explore the impact of digital technology tools on patient adherence to therapy.

Methods

Overview

DIAPAsOn was a non-randomized, prospective, non-interventional observational study conducted at more than 100 centers in the Russian Federation to explore adherence to a prescription of EPA/DHA=1.2/1-90% as either a secondary preventive medical therapy for patients with a history of recent MI (approved dose 1g/day) or for blood lipid regulation in patients with endogenous hypertriglyceridemia that had proved insufficiently responsive to either dietary modification or other drug therapy (approved dose 2-4 g/day). As the objectives of the program are exploratory, there is no formal study hypothesis and no formal calculation of sample size: however, it was planned to enroll 3000 patients.

There is no control group in DIAPAsOn and patients do not undergo additional diagnostic tests or interventions other than those provided for by currently accepted standards of medical care.

A feature of DIAPAsOn is the use of digital technology to facilitate patient-initiated data collection. Patients have access to a customized electronic system that allowed them to enter data, including daily records of EPA/DHA=1.2/1-90% administration, and to complete various questionnaires relating to, for example, health-related quality of life (HRQoL) and product usability on a four-grade scale (very good, good, moderate, poor). If the reported grade is 'moderate' or 'poor', patients were asked to provide narrative details for this assessment.

This facility includes an option for patients to set up reminders to take the study medication. Patients are also able to report side effects in their personal accounts or to indicate if they had undergone any hospitalizations due to cardiovascular reasons, new cases of angina pectoris or non-fatal MI.

DIAPAsOn is registered at www.ClinicalTrials.gov (NCT03415152).

Recruitment of study centers and patients

Selection of investigators and sites to participate in the program was based on the following requirements:

- (1) The ability to properly conduct the program, including capacity to complete an electronic case record form.
- (2) Existence within the study center of a cohort of adult (≥ 18 years) patients with a history of MI not earlier than 6 months previously for whom EPA/DHA=1.2/1-90% was prescribed as part of a medical secondary prevention regimen and/or existence within the study center of a cohort of patients with a diagnosis of hypertriglyceridemia not adequately controlled by a hypolipidemic diet.

Patients provisionally satisfying the criteria set out in (2) were eligible to participate in DIAPAsOn if they had been taking EPA/DHA=1.2/1-90% for no more than 14 days at the time of enrolment and if they were considered capable, either personally or with the assistance of immediate relatives, of submitting data through a mobile phone app or web browser.

Candidates for enrolment were excluded if they were taking medications other prescription-only omega-3 PUFA products or nutrition supplements containing omega-3 PUFAs at screening or had taken such compounds within the previous 6 months. Other exclusion criteria comprised:

- Pregnancy or breastfeeding.
- Known sensitivity to the active substance, excipients or soy.
- Exogenous hypertriglyceridemia (Frederikson type I hyperchylomicronemia).
- Current participation in any other clinical or observational study, or involvement within the previous 30 days.
- Any other clinical state that, in the opinion of the center investigator, made the patient unsuited to inclusion.

Objectives and endpoints

The primary objective of DIAPAsOn was to assess adherence to therapy with EPA/DHA=1.2/1-90% in post-MI patients or patients with hypertriglyceridemia.

Secondary goals included evaluation of:

- reasons for termination of the study therapy
- in-study HRQoL
- health outcomes in the different patient subgroups.

Schedule of visits and data collection

Three principal clinic visits featured in the timeline of the DIAPAsOn study, as illustrated in **Figure 1**. At each of these, patients were interrogated regarding their adherence to EPA/DHA=1.2/1-90% and their compliance with that therapy was represented by answers to the Questionnaire of Treatment Compliance [24]. This instrument, which has been used to investigate compliance with antihypertensive medication among Russian patients, produces a numerical indication of compliance, as follows: 12–15 points, very high; 8–11 points, high; 4–7, moderate; 0–3, low.

Other information elicited or obtained at these visits included: significant concomitant therapy, blood pressure and heart rate. Because EPA/DHA=1.2/1-90% was administered within the frames of normal medical practice, rather than being supplied by the sponsor, information about the batch number and shelf life of EPA/DHA=1.2/1-90% were also recorded at each visit.

Figure 1. Design and chronology of the DIAPAsOn study.

Blood lipid profile was determined at each clinical presentation. As DIAPAsOn was a non-interventional observational study, no central laboratory procedures were performed. All laboratory tests were conducted in accordance with routine local clinical practice.

Safety and adverse events data were elicited at each visit. In the event of a patient discontinuing the study, enquiries were made about the reasons for this, under the following headings: adverse drug reactions; lack of effect; inconvenience of use; non-availability in pharmacies; other.

The principal clinic visits were supplemented by inter-visit phone calls focused on adherence to therapy and safety.

Mobile patient engagement technology

The electronic patient engagement and data collection system used in DIAPAsOn was developed in collaboration with the medical online platform ROSMED.INFO (Moscow, Russian Federation; www.rosmed.info), which has extensive experience in

the development and operation of such facilities in the Russian Federation, including: the Russian Severe Asthma Registry (RSAR; NCT03608566); the all-Russian register of patients with hearing impairment and the integrated support program (anticipated recruitment 12 million people); and the Russian Register of patients aged >80 years with ACS. ROSMED.INFO is also involved in the maintenance, on behalf of the Russian Glaucoma Society, of the first Russian pharmaco-epidemiological study of the treatment of glaucoma patients with retinoprotective interventions and adherence to therapy.

The system devised for DIAPAsOn is configured to minimize technical and ergonomic barriers to participant adoption and use. Contributing patients may work with the web version (without installing software on a local PC) or may download the relevant app for IOS (Apple) or Android smartphones; all versions of the online platform are configured to work with all popular browsers.

The ROSMED.INFO platform as used in DIAPAsOn is a software product that satisfies current requirements of Russian legislation pertaining to the management of personal data and the implementation of observational studies, primarily Russian Federal Law No. 152.

The ROSMED.INFO platform is included in the Russian Unified Register of computer programs and databases of the Ministry of Communications of Russia. Certification of quality management and information security management is conducted in accordance with ISO 9001: 2015 and ISO/IEC 27001: 2013.

Operational domains of the digital platform are depicted in **Figure 2** and differentiate between an “administrative tier” occupied by the service manager and the study sponsor and an “executive” tier that include dedicated areas (“cabinets”) for use by patients and physicians.

284 **Figure 2.**

USER'S INTERACTION

285

286

287 Specimens of the Physician Cabinet GUI are shown in **Figures 3 & 4** along with a
 288 bulleted summary of the facilities available to physicians (**Figure 3**). (These
 289 screengrabs have been translated into English for the convenience of an
 290 international readership: the working versions are in Russian and are available on
 291 application to the author for correspondence. The examples shown here have also
 292 been anonymized.)

293

Figure 3.

Working zone of the physician-participant of the Registry

- Creating of new charts of patients and visits
- Access to patient profile
- Opening of the patient's chart by other physicians
- Online statistics and analytics
- Upload of data in Excel format
- Internal SMS for patients and physicians
- "Exchange" of new patients

307 **Figure 4.**

ATTACHING OF YOUR PATIENTS AND COMMUNICATION WITH NEW CANDIDATES

The screenshot shows a web browser window with the URL <https://data.rosmed.info/registers/patients/?type=exchange&id=53>. The page title is "Register of patient with myocardial infarction". The interface includes a navigation bar with buttons for "Registers", "Messages", "Notification", "Profile", and "Exit". Below the navigation bar, there is a header section with a logo and the title "Register of patient with myocardial infarction". The main content area features a horizontal menu with tabs: "patients", "records", "live tape", "statistic", "curator", and "manager". Under the "patients" tab, there are sub-tabs: "My patients", "Patients of other doctors", "Patients available to other doctors", "Patients assignment", and a button "TO MAKE PATIENT RECORD". Below the sub-tabs, there is a form with a "Full name" label, a dropdown menu with "Start entering records", a search input field labeled "Search full name", and a "SHOW" button. At the bottom, there is a table with columns: "Photo", "Patient's full name", "Region", and "Status". The "Photo" column contains a placeholder icon and a "Take" button.

308

309 The landing page for the Patient Cabinet is illustrated in **Figure 5** and identifies 5
310 main drop-down menus designed to allow patients easy access to the full range of
311 facilities and services provided by the technology. These include access to notices
312 and push-reminder services (**Figure 6**) and an internal social network (**Figure 7**).
313 The patient registration page has deliberately been kept simple to minimize set-up
314 friction and encourage patient enrolment (**Figure 8**). (These screengrabs have been
315 translated into English for the convenience of an international readership: the
316 working versions are in Russian and are available on application to the author for
317 correspondence. The examples shown here have also been anonymized.)

318 **Figure 5.**

PATIENT'S CABINET

EXAMPLES OF FUNCTIONAL CAPABILITIES OF THE PLATFORM ROSMED.INFO

⊕ ATTACHING TO THE DOCTOR

✍ COMPLETED QUESTIONNAIRES AND SURVEYS

i ACCESS TO REAL DATA INFORMATION ON DISEASE, TREATMENTS, ETC.

🕒 REMINDERS FOR DRUG ADMISSION OR VISIT TO THE DOCTOR

💬 INTERNAL SMS WITH DOCTOR, ONLINE CONSULTATION

320 **Figure 6.**

NOTICES AND PUSH-REMINDER MESSAGES

Reminders of taking the drug, a visit to the doctor or investigations all the information is available in the form of internal messages, notifications that come not only in the online program, but also on the screens of smartphones and tablets (doctor/patient)

321

322

323 **Figure 7.**

INTERNAL SOCIAL NETWORK

324

325 **Figure 8.**

SIMPLIFIED PATIENT'S REGISTRATION

The registration form is titled "SIMPLIFIED PATIENT'S REGISTRATION". It features two tabs: "PATIENT" (selected) and "PHYSICIAN". The form includes input fields for "Email*" (containing "my@mail.ru"), "Password*" (containing "create a password"), and "Repeat password*" (containing "retype your password"). A prominent purple "REGISTER" button is located below these fields. To the right of the input fields, a text box contains the instruction: "Use Quick Registration to create personal patient accounts for yourself and people closest to you". At the bottom left, there is a checkbox labeled "I accept the terms of policies and processing of personal data, I consent to the processing of my personal data". The form is set against a light purple background with a decorative pattern of overlapping circles at the bottom.

PATIENT PHYSICIAN

Email*

my@mail.ru

Password*

create a password

Repeat password*

retype your password

REGISTER

Use Quick Registration to create personal patient accounts for yourself and people closest to you

☐ I accept the terms of policies and processing of personal data, I consent to the processing of my personal data

Statistical and analytical plans

Statistical analysis is performed in accordance with a pre-approved Statistical Analysis Plan, using the statistical programming language R (version 3.4.3. <https://mran.microsoft.com/releases/3.4.3>).

As DIAPAsOn is an open, non-randomized observational program, statistical methods are planned to be mainly descriptive.

Comparison of patient data between scheduled clinical visits is carried out using Student's t-test for dependent samples, or McNemar's test for qualitative data. For all comparisons, statistical significance is calculated. For applicable endpoints, further analysis is performed in subgroups of patients with different adherence rates at Visits 2 and 3.

The primary endpoint is assessed in the per-protocol population, which includes all patients for whom data are collected, at least at Visit 2. The safety population includes all patients who complete at least Visit 1. This population was used to record reports of adverse drug reactions (ADR), serious ADRs (SADR), and other safety information.

Analysis of the primary endpoint includes (1) determination of the mean adherence rate, calculated as the sum of days when the patient took the full prescribed dose of EPA/DHA=1.2/1-90% during the specified period divided by the total number of days in that period, at the end of the study (Visit 3); and (2) mean score on the National Questionnaire of Treatment Compliance, determined at the end of the study (Visit 3).

Ethics

Ethical oversight of the DIAPAsOn study is exercised by the independent Interuniversity Ethics Committee (IEC; Moscow, Russian Federation). Initial written approval of the IEC was issued on 19 October 2017, before the start of the study.

The study was then implemented in accordance with the protocol version of 8 November 2017.

359

360 DIAPAsOn conforms to the requirements of Good Clinical Practice (GCP) and to all
361 applicable national standards relevant to the rights, safety and well-being of all study
362 participants in accordance with the provisions of the Declaration of Helsinki and all
363 relevant national legislation and related provisions. Advanced informed written
364 consent is obtained from the patient to use and/or disclose personal and/or medical
365 information. Prospective patients are apprised of their right to decline further
366 participation in DIAPAsOn at any time and for any declared reason (or for no reason)
367 without prejudice to any subsequent treatment.

368

369 Individual center investigators are responsible for ensuring quality control, execution
370 of the program and the collection, documentation and submission of data in
371 accordance with the protocol, standards of GCP and all applicable local laws.

372

373 Administrative structure

374 The tripartite functional organization of the project is illustrated in **Figure 9**. The
375 study principal investigator is Professor Grigory Pavlovich Arutyunov, Pirogov
376 Russian National Research Medical University, Moscow, Russian Federation. A list
377 of investigators at each of the 108 participating centers is presented in
378 **Supplementary Table 1**.

379

Figure 9.

FUNCTIONAL SCHEME OF THE PROJECT

ROSMED.INFO is responsible for the development and maintenance of software for the digital data collection and adherence facilities, and for data collection and protection.

Contract research services are provided by RSML LLC (Moscow, Russian Federation), and data statistical services by Sciencefiles LLC (Yekaterinburg, Russian Federation).

DIAPAsOn is sponsored by Abbott Laboratories (Moscow, Russian Federation), which is the legal owner of the registry database of digital information generated during the study.

Results

A total of 3000 patients were initially included in the program but 428 (14.3%) were excluded from the program because Visit 1 data were incomplete. Valid and complete data from Visit 1 were available for 2572 patients (85.7%) who constituted the safety population, and data from a per-protocol contingent of 2167 patients was accrued, 405 patients having been lost due to early termination (i.e. before Visit 3).

Within the overall per-protocol population, 898 patients (41.4%) were prescribed EPA/DHA=1.2/1-90% for secondary prevention after MI and 1269 (58.6%) were prescribed EPA/DHA=1.2/1-90% for hypertriglyceridemia. The program was completed per protocol by 1975 patients, 780 of whom were being treated for secondary prevention and 1195 of whom were being treated for hypertriglyceridemia.

Because DIAPAsOn is an observational study, the protocol stipulated that discontinuation of EPA/DHA=1.2/1-90% is not a reason to withdraw a patient from the study.

Detailed tabulations of the demographic profile of the DIAPAsOn patients are provided in **Tables 1 & 2**, sub-stratified according to the reason for treating with EPA/DHA=1.2/1-90% (i.e. secondary prevention post-MI or management of hypertriglyceridemia). In summary, men account for 52.84% of the total population and 67.7% of the subgroup prescribed EPA/DHA=1.2/1-90% for secondary prevention post-MI (n=608); conversely, most of the patients prescribed EPA/DHA=1.2/1-90% for hypertriglyceridemia are women (n=732; 57.68%). The study population is almost exclusively Caucasian (97.74%) and almost all other patients (n=43) were classified as Asian.

Patients' mean age is 59.86 ± 11.62 years, and overall mean body mass index (BMI) is 29.9 ± 5.6 kg/m². Patients in the secondary prevention subgroup are slightly older than those enrolled for hypertriglyceridemia (61.79 ± 10.29 vs. 58.2 ± 12.4 years), whereas the latter have a higher average BMI (31.0 ± 6.4 vs. 28.5 ± 4.1 kg/m²). Just over a quarter of all patients (28.29%) are recorded as active smokers, including 31.63% of patients in the secondary prevention subgroup (hypertriglyceridemia

subgroup, 25.9%). In the secondary prevention subgroup the average time since the index MI to start of study therapy with EPA/DHA=1.2/1-90% is 3.04 ± 1.73 months. The most frequently recorded concomitant diseases identified in the study population at baseline (based on International Classification of Diseases, version 10 codes) comprised 'Hypertensive diseases' (I10–I15), recorded in 63.82% of patients. Within those categories, 'Hypertensive heart disease without congestive heart failure' (33.5% of patients, n=1383) and 'Essential hypertension' (15.1% of patients, n=328) are conspicuous. 'Coronary heart disease' (I20–I25) is recorded in 17.9% of patients (n=388), 'Other heart disease' (I30-I52), including unspecified atrial fibrillation and atrial flutter, in 16.22% (n=352) and 'Diabetes mellitus' in 7.11% of patients (n=1564). 'Metabolic disorders' (E70–E90) are recorded in 10.8% of patients (n=235).

Therapies prescribed during the 12 months preceding enrolment are dominated numerically by lipid-modifying agents, taken by 1600 patients (73.83%). The single most frequently prescribed drug in this category is rosuvastatin (n=906, 41.8% of the per-protocol population), followed by atorvastatin (n=601, 27.7%%). Combinations of lipid-modifying drugs accounted for a further 6.9% (n=150). Just over half the patients (n=1140, 52.6%) have been prescribed anti-platelet agents, primarily aspirin (n=583), and 40.6% (n=879) have been prescribed beta-blockers, predominantly bisoprolol (n=586). A further 694 patients (32%) received angiotensin-converting enzyme (ACE) inhibitors, either as monotherapy (n=438) or in combinations with other classes of antihypertensive drugs, including diuretics and calcium-channel blockers. Perindopril is the most widely prescribed ACE inhibitor (n=325).

Variations are apparent in the two indication-specific subgroups. Thus, among patients who received EPA/DHA=1.2/1-90% for secondary prevention post-MI, use of anticoagulants is recorded in 96.4%, use of beta-blockers in 62.9%, use of ACE inhibitors in 31.9% and use of lipid-modifying agents in 73.6%. Pre-study use of lipid-modifying agents is at a similar level in the subset of patients with hypertriglyceridemia (74.0%) but use of the other classes of agents specified above was at a lower level.

Baseline mean blood pressure is $133.7 \pm 17.3/81.4 \pm 8.8$ mmHg. In the cohort overall, and in the hypertriglyceridemia subset, some 25% of patients are considered to have clinically relevant elevation of systolic blood pressure, compared with 18% of those in the post-MI subgroup. Approximately 13% in both subgroups are considered to have clinically relevant elevation of diastolic blood pressure.

Full analysis of the findings of DIAPAsOn in respect of the influence of patient-facing digital engagement and reporting technologies on adherence to EPA/DHA=1.2/1-90% therapy is in progress and is expected to be the subject of a separate report.

Discussion

Rates of death from CHD have been falling in Russia in recent decades but the rate of decline has been less marked than in other European countries and age-standardized mortality rates remain markedly higher than in other nations [25, 26]. Data from the Know Your Heart survey and other investigations suggest that not all of this discrepancy is explained by blood lipids (alcohol appears to exert a notable influence) but lipids are regarded as central determinants of risk [27,28]. Additional efforts to improve the management of coronary risk are therefore warranted and a focus on patient adherence to secure maximum benefit from available therapies is one logical dimension of that response.

It is clear from the results of the CEPHEUS II study that failure to reach targets for lipid-based risk reduction is widespread in Russia [29]. Patient-related factors associated with non-attainment of targets identified in that study included considering it acceptable to miss prescribed doses more than once per week.

Two-thirds of the patients who participated in DIAPAsOn have concomitant hypertension. Recently published results from the ANICHKOV trial of patients in Russia with both high blood pressure and high cholesterol illustrate the necessity of non-statin therapy in patients with high TG and the difficulties of attaining target levels for both lipids and blood pressure [30].

In response to these deficits, we have developed digital technology tools designed to stimulate patient engagement and education and have recruited 3000 patients to a first trial of the effectiveness of this mobile health technology. We believe this research in preventive cardiovascular medicine to be the first of its kind undertaken at scale in Russia: it may provide a model for further developments in this field.

Limitations of DIAPAsOn must be recognized. As with observational studies in general, the absence of a control group precludes any determination of cause and effect and the potential for biases in any trial of this type must be acknowledged. A retrospective calculation of the Nichol score for DIAPAsOn confirmed that our study rated favorably in the subcategories of ‘Disease-Related Criteria’ and ‘Compliance Definition and Measurement Criteria’ but scored less strongly in ‘Study Design Criteria’. The duration of follow-up is appropriate for a pilot trial of a technical innovation but a substantially longer period of observation will be needed to demonstrate if our strategy for digital patient engagement translates into a robust, sustained and meaningful improvement in long-term compliance and adherence. The online resources are all developed and presented in Russian and the study population is ethnically highly homogeneous: those factors may restrict the generalizability of findings from this study. We have not performed a pre-study evaluation of the online services used in DIAPAsON using, for example, the Mobile App Rating Scale (MARS) and there is no pilot testing phase.

Conclusions

DIAPAsOn is a prospective study of a digital technology and patient self-reporting platform to enhance adherence with EPA/DHA=1.2/1-90% therapy in patients who have experienced a first MI or who have a diagnosis of hypertriglyceridemia. Experience and insight from this study may inform the further development of mobile health engagement technologies for Russian populations to improve compliance and adherence with medications and thereby reduce the risk of clinical cardiovascular events.

Funding and disclosure

The study is supported by Abbott.

GPA has not received any educational grants from any companies and has not received any fees or non-financial support from healthcare companies related to this study. GPA reports receiving honoraria for professional lectures at regional/national medical educational events from healthcare companies, including Abbott, Bayer, Boehringer Ingelheim, Servier.

AGA has not received any educational grants from any companies and has not received any fees or non-financial support from healthcare companies related to this study. AGA reports receiving honoraria for professional lectures at regional/national medical educational events from healthcare companies, including Abbott, Bayer, Boehringer Ingelheim, Servier.

FTA does not have any conflicts of interest.

TVF does not have any conflicts of interest.

Acknowledgements

The investigators thank the Ethics Committee of Pirogov Russian National Research Medical University Ethical for its advice and guidance on the development of the research protocol.

Manuscript preparation was assisted by **Hughes associates**, Oxford, UK.

Table 1. Age, height, weight and BMI data for the overall population and designated subgroups (based safety population with data available from Visit 1; N = 2572).

Overall population (N = 2572)

Parameter	Age (years)	Height (m)	Weight (kg)	BMI (kg/m ²)
Mean	59.86	1.71	87.09	29.89
SD	11.62	0.09	16.85	5.62
Min	20	1.45	42	18.42
Max	93	2.01	195	62.16

Secondary prevention subgroup (N = 1171)

Parameter	Age (years)	Height (m)	Weight (kg)	BMI (kg/m ²)
Mean	61.79	1.73	85.96	28.54
SD	10.29	0.09	15.14	4.08
Min	27	1.48	42	18.42
Max	93	2	165	50.36

Hypertriglyceridemia subgroup (N = 1401)

Parameter	Age (years)	Height (m)	Weight (kg)	BMI (kg/m ²)
Mean	58.24	1.69	88.04	31.01
SD	12.41	0.08	18.11	6.43
Min	20	1.45	49	18.67
Max	89	2.01	195	62.16

Table 2. Sex, education, employment, marital and smoker status for the per-protocol population (N = 2167), subdivided by reason for prescribing EPA/DHA=1.2/1-90%.

	Overall population		Secondary prevention post-MI		Hypertriglyceridemia	
	N	Proportion (%)	N	Proportion (%)	N	Proportion (%)
Sex						
Male	1145	52.84	608	67.71	537	42.32
Female	1022	47.16	290	32.29	732	57.68
Education						
Secondary education drop-out	17	0.78	13	1.45	4	0.32
Secondary general	238	10.98	86	9.58	152	11.98
Secondary vocational	673	31.06	280	31.18	393	30.97
Higher	1199	55.33	504	56.12	695	54.77
Supplementary vocational	40	1.85	15	1.67	25	1.97
Work status						
Working	1199	55.33	445	49.55	754	59.42
Not working	968	44.67	453	50.45	515	40.58
Marital status						
Single	91	4.2	33	3.67	58	4.57
Married	1744	80.48	669	74.5	1075	84.71
Divorced	124	5.72	60	6.68	64	5.04
Widowed	208	9.6	136	15.14	72	5.67
Smoker status						
Smoker	613	28.29	284	31.63	329	25.93
Non-Smoker	1554	71.71	614	68.37	940	74.07

References

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in *Lancet*. 2005 Oct 15-21;366(9494):1358] [published correction appears in *Lancet*. 2008 Jun 21;371(9630):2084]. *Lancet*. 2005;366(9493):1267-1278. doi:10.1016/S0140-6736(05)67394-1
2. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis *JAMA Cardiol*. 2018;3(9):823-828. doi:10.1001/jamacardio.2018.2258
3. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. *Vasc Health Risk Manag*. 2013;9:617-670. doi:10.2147/VHRM.S37119
4. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). *Circulation* 1998;97: 1453e60
5. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. *J Am Coll Cardiol* 2015;65:2267e75.
6. Hussain A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. *Curr Atheroscler Rep*. 2020;22(7):25. Published 2020 Jun 3. doi:10.1007/s11883-020-00846-8
7. Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. *Vasc Health Risk Manag* 2009;5 89–95.
8. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* 2009;302:1993–2000.
9. Lorenzatti AJ, Toth PP. New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. *Eur Cardiol*. 2020;15:1-9. Published 2020 Feb 26. doi:10.15420/ecr.2019.06
10. Vallejo-Vaz AJ, Corral P, Schreier L, Ray KK. Triglycerides and residual risk. *Curr Opin Endocrinol Diabetes Obes*. 2020;27(2):95-103. doi:10.1097/MED.0000000000000530

11. Toth PP, Fazio S, Wong ND, Hull M, Nichols GA. Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. *Diabetes Obes Metab.* 2020;22(3):279-289. doi:10.1111/dom.13921
12. Kolovou GD, Anagnostopoulou K, Pilatis ND, et al. Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia. *Vasc Health Risk Manag.* 2005;1(2):155-161. doi:10.2147/vhrm.1.2.155.64079
13. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J.* 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106
14. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease - executive summary. *Endocr Pract.* 2017;23(4):479-497. doi:10.4158/EP171764.GL
15. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation.* 2011;123(20):2292-2333. doi:10.1161/CIR.0b013e3182160726
16. Li YH, Ueng KC, Jeng JS, et al. 2017 Taiwan lipid guidelines for high risk patients [published correction appears in J Formos Med Assoc. 2018 Aug;117(8):749-750]. *J Formos Med Assoc.* 2017;116(4):217-248. doi:10.1016/j.jfma.2016.11.013
17. Prattichizzo F, Giuliani A, Sabbatinelli J, et al. Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes [published online ahead of print, 2020 May 11]. *Diabetes Obes Metab.* 2020;10.1111/dom.14081. doi:10.1111/dom.14081
18. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. *Diabetes Obes Metab.* 2019 Feb;21(2):366-371. doi: 10.1111/dom.13537
19. Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease

- 676 Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition
677 Examination Survey 2007-2014. *Diabetes Care*. 2019;42(12):2307-2314.
678 doi:10.2337/dc19-0501
- 679 20. Gutstein AS, Copple T. Cardiovascular disease and omega-3s: Prescription
680 products and fish oil dietary supplements are not the same. *J Am Assoc*
681 *Nurse Pract*. 2017;29(12):791-801. doi:10.1002/2327-6924.12535
682
- 683 21. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the
684 primary and secondary prevention of cardiovascular disease. *Cochrane*
685 *Database Syst Rev*. 2020;3(2):CD003177. Published 2020 Feb 29.
686 doi:10.1002/14651858.CD003177.pub5
687
- 688 22. Brown WV, Jacobson TA, Braun LT. Achieving adherence to lipid-lowering
689 regimens. *J Clin Lipidol*. 2013;7(1):4-13. doi:10.1016/j.jacl.2012.11.004
- 690 23. Redfern J. Smart health and innovation: facilitating health-related behaviour
691 change. *Proc Nutr Soc*. 2017;76(3):328-332.
692 doi:10.1017/S0029665117001094
- 693 24. Fofanova T.V., Ageev F.T., Smirnova M.D., Svirida O.N., Kuzmina A.E.,
694 Thostov A.Sh., Nelyubina A.S. National questionnaire of treatment
695 compliance: testing and application in outpatient practice // *Systemic*
696 *hypertension* | #2 | 2014, p. 13-16
- 697 25. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe:
698 epidemiological update 2016. *Eur Heart J* 2016;37:3232–45.
- 699 26. Grigoriev P, Meslé F, Shkolnikov VM, et al. The recent mortality decline in
700 Russia: beginning of the cardiovascular revolution? *Popul Dev Rev*
701 2014;40:107–29.
- 702 27. Iakunchykova O, Averina M, Kudryavtsev AV, et al. Evidence for a Direct
703 Harmful Effect of Alcohol on Myocardial Health: A Large Cross-Sectional
704 Study of Consumption Patterns and Cardiovascular Disease Risk Biomarkers
705 From Northwest Russia, 2015 to 2017. *J Am Heart Assoc*.
706 2020;9(1):e014491. doi:10.1161/JAHA.119.014491
- 707 28. Iakunchykova O, Averina M, Wilsaard T, et al. Why does Russia have such
708 high cardiovascular mortality rates? Comparisons of blood-based biomarkers
709 with Norway implicate non-ischaemic cardiac damage. *J Epidemiol*
710 *Community Health* Published Online First: 15 May 2020. doi: 10.1136/jech-
711 2020-213885.
- 712 29. Boytsov S, Logunova N, Khomitskaya Y; CEPHEUS II investigators.
713 Suboptimal control of lipid levels: results from the non-interventional
714 Centralized Pan-Russian Survey of the Undertreatment of
715 Hypercholesterolemia II (CEPHEUS II). *Cardiovasc Diabetol*. 2017;16(1):158.
716 Published 2017 Dec 16. doi:10.1186/s12933-017-0641-4.
717

- 718 30. Sergienko IV, Ansheles AA, Drapkina OM, et al. ANICHKOV study: the effect
719 of combined hypotensive and lipid-lowering therapy on cardiovascular
720 complications in patients of high and very high risk. Ter Arkh. 2019 May
721 16;91(4):90-98. doi: 10.26442/00403660.2019.04.000104. PMID: 31094482.

Supplementary Table 1. Acknowledgement of DIAPASoN centre investigators.

Region	Investigator
Astrakhan Oblast	1. Borodulya Mihail Vasil'evich
Bryansk Oblast	2. Petuhova Irina Leonidovna
Vladimir Oblast	3. Timofeeva Irina Vladimirovna
Volgograd Oblast	4. Vorob'eva Svetlana Gennad'evna
	5. Gulova Ol'ga Aleksandrovna
	6. Dugencova Larisa Anatol'evna
	7. Sytilina Natal'ya Nikolaevna
Voronezh Oblast	8. Trubicyna Irina Valentinovna
Kemerovo Oblast	9. Krestova Ol'ga Sergeevna
Krasnodar Krai	10. Alekseeva Elena Valer'evna
	11. Allaabed Hassan Adnanovich
	12. Bahmet'eva Irina Aleksandrovna
	13. Boldin Vasilij Borisovich
	14. Vikulova Larisa Vladimirovna
	15. Golovko Artyom Yur'evich
	16. Emuzova Liana Anatol'evna
	17. Zaharov Aleksandr Yur'evich
	18. Ivochkina Marina Ivanovna
	19. Imamutdinova Marina Vladimirovna
	20. Kovalenko Fyodor Andreevich
	21. Minasyan Ani Kamoevna
	22. Mkrtycheva Angelina Gennad'evna
	23. Nikitina Elena Valer'evna
	24. Novikova Svetlana Valer'evna

Region	Investigator
	25. Pavlovec Vadim Petrovich
	26. Perkova Elena Mihajlovna
	27. Prozorovskaya Yuliya Igorevna
	28. Ramenskaya Tat'yana Evgen'evna
	29. Raff Stanislav Anatol'evich
	30. Smolina Elena Garievna
	31. Subbotina Anastasiya Vladimirovna
	32. Tatarinceva Zoya Gennad'evna
	33. Usmanova Natal'ya Aleksandrovna
	34. Hazhbieva Milana Musaevna
	35. Shadzhe Evgeniya Azamatovna
Krasnoyarsk Krai	36. Hamyt- Kyzy Ajperi Hamytovna
Moscow	37. Adamyan Margarita Mamikonovna
	38. Belov Leonid L'vovich
	39. Brodichko Alena Ivanovna
	40. Bugaev Timofej Dmitrievich
	41. Vahrulina Natal'ya Konstantinovna
	42. Grigor'eva Ekaterina Anatol'evna
	43. Dvorina Ol'ga Gennad'evna
	44. Dmitrieva Irina Mihajlovna
	45. Karaeva Aida Anzorovna
	46. Novosel'ceva Ekaterina Pavlovna
	47. Oganessian Lala Konstantinovna
	48. Polyakova Natal'ya Olegovna
	49. Ryzhova Tat'yana Vladimirovna
	50. Smirnova Ol'ga L'vovna

Region	Investigator
	51. Tavleeva Svetlana Nikolaevna
	52. Hrulenko Svetlana Borisovna
	53. Chernushenko Tat'yana Ivanovna
Moscow Oblast	54. Gukov Konstantin Aleksandrovich
	55. Gukova Tat'yana Sergeevna
	56. Malyarenko Elena Nikolaevna
	57. Sorokin Sergej Anatol'evich
Nizhny Novgorod Oblast	58. Abramova Nataliya Arkad'evna
	59. Aksenova Nataliya Aleksandrovna
	60. Barsukova Nataliya Aleksandrovna
	61. Budarina Yuliya Gennad'evna
	62. Grushin Dmitrij Valer'evich
	63. Kolesnichenko Irina Vyacheslavovna
	64. Lokonova Larisa Mihajlovna
	65. Fedorova Svetlana Nikolaevna
Novosibirsk Oblast	66. Shurkevich Anastasiya Alekseevna
Omsk Oblast	67. Minzhasarova Saniya Hasangalievna
	68. Naumov Dmitrij Valer'evich
Perm Krai	69. Zhuravleva Natal'ya Alekseevna
The Republic of Adygea	70. Shekhmirzova Dzhanetta Ruslanovna
The Republic of Bashkortostan	71. Gilyaeva El'vira Fanisovna
	72. Dmitriev Aleksej Valer'evich
	73. Murasova Rimma Ismagilovna
	74. Tarzimanova Yuliya Shamilevna
	75. Timerbulatov Timur Rasfarovich
Tatarstan	76. Ivanova Natal'ya Mihajlovna

Region	Investigator
Rostov Oblast	77. Budanova Ol'ga Veniaminovna
	78. Lobe Aleksandra Ovanesovna
	79. Mazruho Marina Karpovna
	80. Morgun Nina Karpovna
	81. Stupina Anna Alekseevna
Ryazan Oblast	82. Grusheckaya Irina Stanislavovna
	83. Samarceva Yana Nikolaevna
Samara Oblast	84. Aristova Tat'yana Vladimirovna
	85. Reznik Irina Mihajlovna
	86. Rybina Evgeniya Dmitrievna
	87. Sapunkova Svetlana Mihajlovna
	88. Filippovskaya Natal'ya Igorevna
	89. Chernova Viktoriya Nikolaevna
Saint Petersburg	90. Bulycheva-Samohina Lyubov' Vasil'evna
	91. Omel'chenko Marina Yur'evna
	92. Saf'yanova Natal'ya Viktorovna
Saratov Oblast	93. Mihajlova Elena Aleksandrovna
Smolensk Oblast	94. Novik Lyudmila Mihajlovna
Stavropol Krai	95. Vedeneva Elena Viktorovna
	96. Eremenko Aleksej Mihajlovich
	97. Kubanova Asiyat Borisovna
	98. Minasova Elena Nikolaevna
Tomsk Oblast	99. Zubova Ol'ga Valer'evna

Tula Oblast	100. Barabanova Tat'yana Yur'evna
	101. Dabizha Viktoriya Gennad'evna
	102. Kolomejceva Tat'yana Mihajlovna
	103. Prihod'ko Tat'yana Nikolaevna
Tumen Oblast	104. Ahshiyatova Nastya Ibragimovna
Khabarovsk Krai	105. Koroleva Ramilya Lotfullovna
Chelyabinsk Oblast	106. Malyutina Anastasiya Gennad'evna
	107. Fanina El'vira Rinatovna

725

726

727

728